spacer
home > ebr > winter 2018 > editor’s letter
PUBLICATIONS
European Biopharmaceutical Review

Editor’s Letter

This edition of EBR went to press just as a major breakthrough in the development of a potential treatment for Huntington’s disease was announced by researchers at University College London. Identifying, isolating and then being able to block synthesis of the defective, toxic proteins responsible for disease pathology has taken decades to accomplish, and a number of articles in our current issue resonate with aspects of this journey from gene to treatment. Although the exact neurological role of the Huntingtin gene product is not yet known, it is a complex, highly polymorphic protein and has the ability to identify even subtle changes from a core range of sequences, and structures of biological relevance through functional approaches such as microarrays could become increasingly valuable tools in disease research. The faulty Huntingtin gene responsible for Huntington’s disease was discovered in 1993.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Dr Deborah O’Neil, Chief Executive and Scientific Officer, NovaBiotics Ltd
spacer
Dr Deborah O’Neil
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioGenes Establishes Scientific Advisory Board

Berlin, Germany, December 12, 2017 / B3C newswire / -- BioGenes GmbH, specializing in ELISA development and production and a global leader in host cell protein (HCP) assay development, today announces the establishment of a Scientific Advisory Board which includes the following four renowned experts:
More info >>

White Papers
 
Industry Events

11th Annual Proteins & Antibodies Congress

16-17 April 2018, Novotel London West Hotel, Hammersmith, London

Oxford Global Conferences are proud to present our esteemed 11thAnnual Proteins & Antibodies Congress 2018, 16th – 17th April 2018, London, UK. Over 450 proteins, antibodies, peptides and biosimilars & biobetters attendees representing global pharmaceutical organizations, leading biotech companies and internationally renowned academic institutions.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement